EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Curcumin versus placebo in benign prostatic hyperplasia: a systematic review and meta-analysis

Diogo Souto Santana, Breno Cordeiro Porto, Rafael Baldissera Cardoso, Guilherme Melchior Maia Lopes, Luiz Guilherme Serrão Gimenez, Carlo Camargo Passerotti, Ronaldo Maia, Fernando Gonçalves Almeida, Rodrigo Afonso da Silva Sardenberg, José Arnaldo Shiomi da Cruz

European Journal of Clinical Pharmacology · 2026-07 · 82 (7)

DOI: 10.1007/s00228-026-04093-9 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 05.06.2026. Verfasst von Diogo Souto Santana und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Curcumin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade Nove De Julho.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Benign prostatic hyperplasia (BPH) is a highly prevalent condition among aging men and a major cause of lower urinary tract symptoms (LUTS). Although α1-adrenoceptor blockers and 5-alpha-reductase inhibitors remain the cornerstone of treatment, their long-term use is frequently limited by adverse effects and suboptimal symptom control. Growing experimental and clinical evidence suggests that chronic prostatic inflammation plays a central role in BPH progression, raising interest in anti-inflammatory compounds such as curcumin. However, the clinical effectiveness of curcumin in BPH remains poorly defined.

Methods

We conducted a systematic review and meta-analysis of randomized and nonrandomized comparative studies evaluating curcumin versus placebo in men with BPH receiving α-blockers and/or 5-alpha-reductase inhibitors. Searches were performed in PubMed, Embase, and Cochrane CENTRAL. The primary outcome was change in International Prostate Symptom Score (IPSS). Secondary outcomes included prostate-specific antigen (PSA), prostate volume (PV), post-void residual volume (PVR), and maximum urinary flow rate (Q-max). Pooled analyses were performed using a random-effects model.

Results

Six studies involving 697 patients met the inclusion criteria. Compared with placebo, curcumin was associated with a significant improvement in IPSS (MD − 4.11; p = 0.0009), accompanied by reductions in PSA (MD − 0.52 ng/mL), PV (MD − 3.78 mL), and PVR (MD -2.38 mL), as well as an increase in Q-max (MD 2.09 mL/s). Subgroup analyses suggested greater symptomatic benefit among patients receiving α-blockers alone compared with those on combined α-blocker and 5-alpha-reductase inhibitor therapy. Substantial heterogeneity was observed across outcomes.

Conclusion

Curcumin supplementation was associated with significant improvement in LUTS and functional parameters in men with BPH. Although these findings support a potential adjunctive role for curcumin, the available evidence is limited by heterogeneity and study design variability. Well-designed, large-scale randomized trials are warranted to define its clinical utility, optimal formulation, and long-term effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic HyperplasiaCurcuminMaleHumans5-alpha Reductase Inhibitors

Stichwörter der Autor:innen

CurcumaMeta-analysisProstatic hyperplasiaSystematic review

Substanzen

Curcumin5-alpha Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil.
  • Research Institute - Hapvida NotreDame, São Paulo, Brazil.
  • Moinhos de Vento Hospital - Porto Alegre, Rio Grande Do Sul, Brazil.
  • University Centre FMABC - Santo Andre, São Paulo, Brazil.
  • Universidade de São Paulo - School of Medicine, São Paulo, Brazil.
  • Research Institute - Hapvida NotreDame, São Paulo, Brazil. arnaldoshiomi@yahoo.com.br.

Förderung

  • Universidade Nove De Julho

Zitieren

APA

Santana, D. S., Porto, B. C., Cardoso, R. B., Lopes, G. M. M., Gimenez, L. G. S., Passerotti, C. C., Maia, R., Almeida, F. G., da Silva Sardenberg, R. A., & da Cruz, J. A. S. (2026). Curcumin versus placebo in benign prostatic hyperplasia: a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 82(7). https://doi.org/10.1007/s00228-026-04093-9

Vancouver

Santana DS, Porto BC, Cardoso RB, Lopes GMM, Gimenez LGS, Passerotti CC, et al. Curcumin versus placebo in benign prostatic hyperplasia: a systematic review and meta-analysis. European Journal of Clinical Pharmacology. 2026;82(7). doi:10.1007/s00228-026-04093-9

BibTeX
@article{Santana2026,
  author = {Santana, Diogo Souto and Porto, Breno Cordeiro and Cardoso, Rafael Baldissera and Lopes, Guilherme Melchior Maia and Gimenez, Luiz Guilherme Serrão and Passerotti, Carlo Camargo and Maia, Ronaldo and Almeida, Fernando Gonçalves and da Silva Sardenberg, Rodrigo Afonso and da Cruz, José Arnaldo Shiomi},
  title = {Curcumin versus placebo in benign prostatic hyperplasia: a systematic review and meta-analysis},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  volume = {82},
  number = {7},
  doi = {10.1007/s00228-026-04093-9}
}
Kostenlos starten →